HLA plays an important role in apheresis, transfusion medicine, and solid organ and hematopoietic progenitor cell transplantation. There are multiple HLA testing methodologies and complex nomenclature which make interpretation challenging. Transfusion Medicine and Apheresis Practitioners are expected to utilize the tests and interpret results in many clinical scenarios. This session will describe HLA nomenclature and basic principles of HLA testing and discuss interpretations of HLA testing with an emphasis on clinical scenarios related to transfusion medicine, apheresis and transplantation (both solid organ and hematopoietic stem cell transplant), such as platelet refractoriness and apheresis regimens. Furthermore, a discussion of various factors that can affect test results and interpretations will be provided.
Examine the rationale of using therapeutic apheresis in patients with hyperviscosity syndromes due to paraproteins, hyperleukocytosis, polycythemia, or thrombocytosis.
Update the evidence and limitations of therapeutic leukocytapheresis or therapeutic thrombocytapheresis, automated red cell depletion/therapeutic phlebotomy.
Review the technical specifications and procedural considerations of therapeutic leukocytapheresis or therapeutic thrombocytapheresis.
Discuss step-by-step instructions to overcome technical/procedural challenges in cellular depletion procedures in pediatric population and review different alternatives to automated procedures.
Professor of Pathology, Director of Transfusion Medicine, Associate Director, Immunogenetics and Transplantation Laboratory, Associate Director, Pathology Residency Training Program,
University of California San Diego